论文部分内容阅读
目的：探讨联合应用肝纤Ⅰ号和超氧化物歧化酶脂质体（ＳＯＤＬ）对慢性乙型肝炎患者肝纤维化的治疗作用。方法：６３例慢性乙型肝炎患者随机分为治疗组（３３例）和对照组（３０例）。对照组用常规方法治疗，治疗组在常规方法的基础上加用肝纤Ⅰ号和ＳＯＤＬ。观察两组患者治疗前后血清肝纤维化指标（ＰＣⅢ、ＨＡ、ＬＮ）变化，同时观察肝功能、自由基、淋巴细胞亚群及乙型肝炎病毒标志物的变化。结果：治疗组在治疗前后血清ＰＣⅢ、ＨＡ、ＬＮ明显下降，而对照组无显著性变化，其中ＨＢＶＤＮＡ阴转者ＰＣⅢ、ＨＡ、ＬＮ下降最为显著。治疗组肝功能恢复程度、自由基及淋巴细胞亚群的改变也明显优于对照组。结论：两药联合应用对慢性乙型肝炎患者肝纤维化有较好的治疗作用，其抗肝纤维化作用与抗病毒作用密切相关。
Objective: To investigate the therapeutic effect of combined application of liver fibrosis Ⅰ and superoxide dismutase liposome (SODL) on liver fibrosis in patients with chronic hepatitis B. Methods: Sixty-three patients with chronic hepatitis B were randomly divided into treatment group (33 cases) and control group (30 cases). The control group with conventional methods of treatment, the treatment group on the basis of conventional methods plus liver fibrosis Ⅰ and SOD L. The change of serum fibrotic index (PCⅢ, HA, LN) and the change of liver function, free radical, lymphocyte subsets and hepatitis B virus markers were observed before and after treatment. Results: Before and after treatment, the serum PCⅢ, HA and LN in the treatment group decreased significantly, while the control group showed no significant changes. Among them, the PCⅢ, HA and LN in HBVDNA negative conversion were the most significant. The degree of recovery of liver function, the changes of free radicals and lymphocyte subsets in the treatment group were also significantly better than those in the control group. Conclusion: The combination of the two drugs has a good therapeutic effect on liver fibrosis in patients with chronic hepatitis B, and its anti-hepatic fibrosis is closely related to antiviral effect.